Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Zai Lab Ltd Director's Dealing 2021

Jun 18, 2021

31208_dirs_2021-06-17_86e71afe-1b22-4bdf-9ac5-eade4b4ad650.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Zai Lab Ltd (ZLAB)
CIK: 0001704292
Period of Report: 2021-06-16

Reporting Person: Reinhart Harald (Chief Medical Officer)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2021-06-16 Ordinary Shares M 8000 $20.90 Acquired 8000 Direct
2021-06-16 Ordinary Shares S 8000 $162.71 Disposed 0 Direct
2021-06-17 Ordinary Shares M 8000 $18.00 Acquired 8000 Direct
2021-06-17 Ordinary Shares S 8000 $161.64 Disposed 0 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2021-06-16 Stock Options (Right to Buy) $20.90 M 8000 Disposed 2028-03-28 Ordinary Shares (8000) Direct
2021-06-17 Stock Options (Right to Buy) $18.00 M 8000 Disposed 2027-09-20 Ordinary Shares (8000) Direct

Footnotes

F1: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 17, 2021, expires August 30, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

F2: The options vest in equal annual installments over five years beginning on 03/28/2019, the first anniversary of the date of grant.

F3: The options vest in equal annual installments over five years beginning on 09/20/2018, the first anniversary of the date of grant.